Bio-Gene Technology Limited

ASX:BGT Stock Report

Market Cap: AU$7.4m

Bio-Gene Technology Management

Management criteria checks 4/4

Bio-Gene Technology's CEO is Tim Grogan, appointed in Aug 2023, has a tenure of 3.08 years. total yearly compensation is A$348.32K, comprised of 89.3% salary and 10.7% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth A$8.11K. The average tenure of the management team and the board of directors is 3.1 years and 4.4 years respectively.

Key information

Tim Grogan

Chief executive officer

AU$348.3k

Total compensation

CEO salary percentage89.29%
CEO tenure3.1yrs
CEO ownership0.1%
Management average tenure3.1yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Analysis Article • Feb 22

We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Oct 25

Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jun 20

Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Apr 28

Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near Future

Bio-Gene Technology Limited ( ASX:BGT ) is possibly approaching a major achievement in its business, so we would like...
Analysis Article • Jan 11

What We Learned About Bio-Gene Technology's (ASX:BGT) CEO Compensation

Richard Jagger has been the CEO of Bio-Gene Technology Limited ( ASX:BGT ) since 2018, and this article will examine...

CEO Compensation Analysis

How has Tim Grogan's remuneration changed compared to Bio-Gene Technology's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026AU$348kAU$311k

-AU$2m

Mar 31 2026n/an/a

-AU$2m

Dec 31 2025n/an/a

-AU$3m

Sep 30 2025n/an/a

-AU$3m

Jun 30 2025AU$399kAU$312k

-AU$3m

Mar 31 2025n/an/a

-AU$2m

Dec 31 2024n/an/a

-AU$2m

Sep 30 2024n/an/a

-AU$2m

Jun 30 2024AU$286kAU$258k

-AU$2m

Compensation vs Market: Tim's total compensation ($USD248.08K) is about average for companies of similar size in the Australian market ($USD339.01K).

Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.

CEO

Tim Grogan

3.1yrs
Tenure
AU$348,323
Compensation

Mr. Timothy Owen Grogan, LLB, B.Sc., also known as Tim, serves as Managing Director, Chief Executive Officer & Director of Bio-Gene Technology Limited since August 28, 2023. He serves as a Director of Cons...

Leadership Team

NamePositionTenureCompensationOwnership
Timothy Grogan
MD, CEO & Director3.1yrsAU$348.32k0.11%
A$ 8.1k
Drew Speedy
CFO & Company Secretaryless than a yearAU$162.58kno data
Peter May
Executive Director of Research & Development and Executive Director8.7yrsAU$227.29k0.52%
A$ 38.4k
3.1yrs
Average Tenure

Experienced Management: BGT's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Timothy Grogan
MD, CEO & Director3.1yrsAU$348.32k0.11%
A$ 8.1k
Peter May
Executive Director of Research & Development and Executive Director11.3yrsAU$227.29k0.52%
A$ 38.4k
Andrew Guthrie
Non-Executive Director5.4yrsAU$59.77k0.16%
A$ 11.6k
Catherine Hill
Member of the Scientific Advisory Board8.6yrsno datano data
Neil Anderson
Member of Scientific Advisory Boardno datano datano data
Huong Soo Ding
Non-Executive Chairman3.3yrsAU$75.37k0.028%
A$ 2.1k
Christopher Ramsay
Non-Executive Director3.3yrsAU$52.00k0.073%
A$ 5.4k
4.4yrs
Average Tenure

Experienced Board: BGT's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/15 02:05
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2026/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bio-Gene Technology Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tom WaitePAC Partners Securities Pty. Ltd.